öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º¶¡ÑÞ·¼
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º75

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£º»ù´¡Ò½Ñ§Ôº
Ö°³Æ£º¸±½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º
Ñо¿ÁìÓò£º £¨1£©miRNAÔÚÉöСÇò·¢Óý¼°¼²²¡ÖеĻùÒò±í´ïÓëµ÷¿Ø£»£¨2£©miRNAÔÚÂѳ²°©Ô­·¢ÐÔÄÍÒ©ÖÐ... [Õ¹¿ª]


Ñо¿ÁìÓò£º £¨1£©miRNAÔÚÉöСÇò·¢Óý¼°¼²²¡ÖеĻùÒò±í´ïÓëµ÷¿Ø£»£¨2£©miRNAÔÚÂѳ²°©Ô­·¢ÐÔÄÍÒ©ÖеĻùÒò±í´ïÓëµ÷¿Ø¡£ [ÊÕÆð]




ͨѶ·½Ê½ :
°ì¹«µç»°£º**
µç×ÓÓʼþ£ºdingyanfang1201@sina.com


¸öÈ˼òÊö :
¶¡ÑÞ·¼£¬Ë¶Ê¿£¬¸±½ÌÊÚ£¬Ë¶Ê¿Éúµ¼Ê¦¡£2000Äê±ÏÒµÓÚ´óÁ¬Ò½¿Æ´óѧ¸¾²ú¿ÆѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØ,»ñѧʿѧλ,2003Äê»ñ´óÁ¬Ò½¿Æ´óѧÈËÌå½âÆÊÓë×éÖ¯Åß̥ѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØ˶ʿѧλ¡£×Ô±ÏÒµÒÔÀ´£¬Ò»Ö±ÔÚ´óÁ¬Ò½¿Æ´óѧ×éÖ¯Åß̥ѧ½ÌÑÐÊÒÈνÌ¡£Ö÷³Ö¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÒ»Ï´óÁ¬ÊпƼ¼ÏîÄ¿Ò»Ï×÷ΪÖ÷Òª²ÎÓëÕ߲μӿƼ¼²¿¹ú¼ÊºÏ×÷ÏîÄ¿¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð¼°Ê¡Êм¶ÏîÄ¿Ê®ÓàÏî¡£ÒÔµÚÒ»×÷ÕߺÍͨѶ×÷ÕßµÄÉí·Ý·¢±íSCIÂÛÎĺͺËÐÄÆÚ¿¯ÂÛÎÄÊ®Óàƪ¡£×÷ΪÖ÷Òª³ÉÔ±»ñµÃÁÉÄþÊ¡¿Æѧ¼¼ÊõÈýµÈ½±Ò»Ï»ñÊÚȨ·¢Ã÷רÀû2Ïî¡£Ö÷Òª³Ðµ£ÁôѧÉú¼°±¾¿Æ½Ìѧ£¬»ý¼«²ÎÓë½ÌÓý¸Ä¸ï£¬²ÎÓë±àдÈËÎÀ¡¢¿Æѧ¼°Ç廪´óѧ³ö°æÉç¹æ»®½Ì²Ä¼°×¨Öø5²¿¡£

¿ÆÑй¤×÷ :
³Ðµ£µÄ¹ú¼Ò¼¶ÏîÄ¿£º£¨½ü5Ä꣩
1.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿£¬miR-497½éµ¼¾ÖÔî½Ú¶ÎÐÔÉöСÇòÓ²»¯£¨FSGS)×ãϸ°ûËðÉ˵ĻúÖÆÑо¿£¨**£©,2017/01-2019/12£¬ÅÅÃû1
2..973¿Æ¼¼¼Æ»®ÏîÄ¿×Ó¿ÎÌ⣬³£¼ûÉöСÇò¼²²¡·¢»úÖƼ°ÆäÔçÆÚÕï¶Ï(2012CB517600)£¬2012/01-2016/12,ÅÅÃû 2
3.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÇàÄê»ù½ð£¬»ùÓÚRNA aptamerÖ÷¶¯°ÐÏòÓÚÖ×Áö¸Éϸ°ûµÄÄÉÃ×½ðÔØҩϵͳµÄ¹¹½¨ºÍÑо¿£¨**£©,2012/01-2015/12£¬ÅÅÃû 2
´ú±íÐÔÂÛÎÄ£¨½ü5Ä꣩£º
Àý£º×÷Õß¡¢ÎÄÕÂÌâÄ¿¡¢ÔÓÖ¾Ãû³Æ£¨Ó°ÏìÒò×Ó£©¡¢¾íÆÚ¡¢Ò³Âë
[1] Zhang X ,Guo G ,Wang G,Zhao J,Wang B,Yu X ,Ding Y,Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma£¬Molecular Medicine Reports (IF=1.559)£¬2015,12(6)£º8021-8031.(ͨѶ×÷Õß)
[2] Zhao H, Ding Y,Tie B,Sun ZF,Jiang JY,Zhao J,Lin X,Cui S.miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC£¬International Journal of Oncology(IF=3.018),2013,43(3)£º839-849.(²¢ÁеÚÒ»×÷Õß)
[3] Ding YF,Wang G.,Zhao J, Wu X,Cui M,Li T, Li Y, Cui S.The role of miR-200c in ovarian cancer patients with paclitaxel resistance. International Journal of Gynecological Cancer.(IF=2.116),2016,26(suppl 3):672-672
[4] DingY, Zhang X, Cui S.Role of miR-206 in cisplatin resistance of ovarian serous carcinoma.International Journal of Gynecological Cancer (IF=1.958) 2014, 24 (9) : 88-88
[5] Zhao HN,Yu XT,Ding YF,Zhao JY,Wang G ,Wu X,Jiang JY ,Peng C ,Guo GZ, Cui SY.MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2, ONCOTARGET (IF = 5), 7( 33): 53254-53268
[6] Wang YT, Wang CY , Zhao J,Ding YF, Li L .A cost-effective method to prepare curcumin nanosuspensions with enhanced oral bioavailabilityJOURNAL OF COLLOID AND INTERFACE SCIENCE(IF=3.782)£¬485 : 91-98
[7] Xu YW ,Wang CY ,Ding YF , Wang YT,Liu KX ,Tian Y ,Gao M, Li Z ,Zhang JB,Li, L .Nanoparticles with Optimal Ratiometric Co-Delivery of Docetaxel with Gambogic Acid for Treatment of Multidrug-Resistant Breast Cancer. JOURNAL OFBIOMEDICAL NANOTECHNOLOGY(IF=3.929),201612(9) :1774-1781
[8] Zhao H,Liu S,Wang G,Wu X,Ding Y,Guo G,Jiang J ,Cui S .Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer, Oncology Reports(IF=2.6),2014,33(2)£º591-598.
[9] Yu X,Zhang X ,Bi T£¬Ding Y, Zhao J,Wang C,Jia T,Han D,Guo G£¬Wang B£¬Jiang J,Cui S£¬MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma£¬Tumor Biology(IF=2.5),2013,34£¨6£©£º3501-3508.
[10] Zhao JY,Liu CQ,Zhao H,Ding YF,Bi T,Wang B,Lin XC,Guo G, Cui SY. Synchronous detection of miRNAs, their targets and downstream proteinsin transferred FFPE sections: Applications in clinical and basic research£¬Methods(IF=3.7)£¬2012,58(2)£º156-163

½ÌÓý±³¾° :
2000Äê9Ô¡ª2003Äê7Ô ҽѧ˶ʿ ´óÁ¬Ò½¿Æ´óѧ£»1995Äê9Ô¡ª2000Äê7Ô ҽѧѧʿ ´óÁ¬Ò½¿Æ´óѧ